Biologics Market - 2026-2032

January 2026 | 35 pages | ID: B0BE2905B713EN
DataM Intelligence

Abstracts

Biologics Market reached US$ 472.71 billion in 2023 and is expected to reach US$ 966.98 billion by 2033, growing with a CAGR of 7.10% during the forecast period 2026-2033.

The Biologics Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

A Biologics Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

By Product Type

• Monoclonal Antibodies (mAbs)*
• Vaccines
• Recombinant Hormones/Proteins
• Cell Therapy
• Gene Therapy
• Antisense & RNAi Therapeutics
• Others

By Application

• Oncology*
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Disorders
• Neurological Disorders
• Metabolic Disorders
• Others

By Manufacturing

• In-house Manufacturing*
• Outsourced/Contract Manufacturing

By End User

• Pharmaceutical and Biotechnology Companies*
• Hospitals
• Research & Academic Institutes
• Others

Regional Analysis for Biologics Market:

• North America (U.S., Canada, Mexico)
• Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
• Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
• South America (Colombia, Brazil, Argentina, Rest of South America)
• Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

This Report Covers:

• Go-to-market Strategy.
• Neutral perspective on the market performance.
• Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
• Customized regional/country reports as per request and country level analysis.
• Potential & niche segments and regions exhibiting promising growth covered.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).

Research Process:

Both primary and secondary data sources have been used in the global Biologics Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Contents

1. MARKET INTRODUCTION AND SCOPE

1.1. Objectives of the Report
1.2. Report Coverage & Definitions
1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

2.1. Market Highlights and Strategic Takeaways
2.2. Key Trends and Future Projections
2.3. Snippet by Product Type
2.4. Snippet by Application
2.5. Snippet by Manufacturing
2.6. Snippet by End User
2.7. Snippet by Region

3. DYNAMICS

3.1. Impacting Factors
  3.1.1. Drivers
    3.1.1.1. Rising Prevalence of Chronic and Rare Diseases
    3.1.1.2. Increasing Adoption of Targeted Therapies (mAbs, cell & gene therapies)
  3.1.2. Restraints
    3.1.2.1. High Cost of Biologics Development and Treatment
    3.1.2.2. Stringent Regulatory Approval Process
  3.1.3. Opportunity
    3.1.3.1. Expanding Biosimilars Market
    3.1.3.2. Growing R&D in Personalized Medicine and Advanced Therapies
  3.1.4. Impact Analysis

4. GLOBAL BIOLOGICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

4.1. Market Leaders and Pioneers
  4.1.1. Emerging Pioneers and Prominent Players
  4.1.2. Established leaders with largest largest-selling Brand
  4.1.3. Market leaders with established products & Services
4.2. Product Developments and Breakthroughs
4.3. Regulatory and Reimbursement Landscape
  4.3.1. North America
  4.3.2. Europe
  4.3.3. Asia Pacific
  4.3.4. South America
  4.3.5. Middle East & Africa
4.4. Porter’s Five Force Analysis
4.5. Supply Chain Analysis
4.6. Patent Analysis
4.7. SWOT Analysis
4.8. Unmet Needs and Gaps
4.9. Recommended Strategies for Market Entry and Expansion
4.10. Pricing Analysis and Price Dynamics

5. GLOBAL BIOLOGICS MARKET: BY PRODUCT TYPE

5.1. Introduction
  5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  5.1.2. Market Attractiveness Index, By Product Type
5.2. Monoclonal Antibodies (mAbs)*
  5.2.1. Introduction
  5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
5.3. Vaccines
5.4. Recombinant Hormones/Proteins
5.5. Cell Therapy
5.6. Gene Therapy
5.7. Antisense & RNAi Therapeutics
5.8. Others

6. GLOBAL BIOLOGICS MARKET: BY APPLICATION

6.1. Introduction
  6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  6.1.2. Market Attractiveness Index, By Application
6.2. Oncology*
  6.2.1. Introduction
  6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Autoimmune Diseases
6.4. Infectious Diseases
6.5. Cardiovascular Disorders
6.6. Neurological Disorders
6.7. Metabolic Disorders
6.8. Others

7. GLOBAL BIOLOGICS MARKET: BY MANUFACTURING

7.1. Introduction
  7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
  7.1.2. Market Attractiveness Index, By Manufacturing
7.2. In-house Manufacturing*
  7.2.1. Introduction
  7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Outsourced/Contract Manufacturing

8. GLOBAL BIOLOGICS MARKET: BY END USER

8.1. Introduction
  8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  8.1.2. Market Attractiveness Index, By End User
8.2. Pharmaceutical and Biotechnology Companies*
  8.2.1. Introduction
  8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hospitals
8.4. Research & Academic Institutes
8.5. Others

9. GLOBAL BIOLOGICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction
  9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  9.1.2. Market Attractiveness Index, By Region
9.2. North America
  9.2.1. Introduction
  9.2.2. Key Region-Specific Dynamics
  9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
  9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.2.7.1. U.S.
    9.2.7.2. Canada
    9.2.7.3. Mexico
9.3. Europe
  9.3.1. Introduction
  9.3.2. Key Region-Specific Dynamics
  9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
  9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.3.7.1. Germany
    9.3.7.2. U.K.
    9.3.7.3. France
    9.3.7.4. Spain
    9.3.7.5. Italy
    9.3.7.6. Rest of Europe
9.4. South America
  9.4.1. Introduction
  9.4.2. Key Region-Specific Dynamics
  9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
  9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.4.7.1. Brazil
    9.4.7.2. Argentina
    9.4.7.3. Rest of South America
9.5. Asia-Pacific
  9.5.1. Introduction
  9.5.2. Key Region-Specific Dynamics
  9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
  9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
  9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    9.5.7.1. China
    9.5.7.2. India
    9.5.7.3. Japan
    9.5.7.4. South Korea
    9.5.7.5. Rest of Asia-Pacific
9.6. Middle East and Africa
  9.6.1. Introduction
  9.6.2. Key Region-Specific Dynamics
  9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Manufacturing
  9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players
10.2. Market Share Analysis and Positioning Matrix
10.3. Strategic Partnerships, Mergers & Acquisitions
10.4. Key Developments in Product Portfolios and Innovations
10.5. Company Benchmarking

11. COMPANY PROFILES

11.1. Roche*
  11.1.1. Company Overview
  11.1.2. Product Portfolio
    11.1.2.1. Product Description
    11.1.2.2. Product Key Performance Indicators (KPIs)
    11.1.2.3. Historic and Forecasted Product Sales
    11.1.2.4. Product Sales Volume
  11.1.3. Financial Overview
    11.1.3.1. Company Revenue
    11.1.3.2. Geographical Revenue Shares
    11.1.3.3. Revenue Forecasts
  11.1.4. Key Developments
    11.1.4.1. Mergers & Acquisitions
    11.1.4.2. Key Product Development Activities
    11.1.4.3. Regulatory Approvals, etc.
    11.1.4.4. SWOT Analysis
11.2. Merck & Co.
11.3. AbbVie
11.4. Pfizer
11.5. AstraZeneca
11.6. Sanofi
11.7. Johnson & Johnson’s
11.8. Bristol-Myers Squibb
11.9. Novartis
11.10. Eli Lilly (LIST NOT EXHAUSTIVE)

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

12.1. Data Collection Methods
12.2. Data Triangulation
12.3. Forecasting Applications
12.4. Data Verification and Validation

13. APPENDIX

13.1. About Us and Services
13.2. Contact Us